AbbVie Inc. Long-Term Debt, Maturity, after Year Five
AbbVie Inc. (ABBV) had Long-Term Debt, Maturity, after Year Five of $39.26 billion as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2026-02-20
- 2025-12-31: Long-Term Debt, Maturity, after Year Five $39.26B.
- 2024-12-31: Long-Term Debt, Maturity, after Year Five $37.42B.
- 2023-12-31: Long-Term Debt, Maturity, after Year Five $33.33B.
- 2022-12-31: Long-Term Debt, Maturity, after Year Five $36.36B.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2025-12-31 | $39.26B 10-K · filed 2026-02-20 |
| 2024-12-31 | $37.42B 10-K · filed 2025-02-14 |
| 2023-12-31 | $33.33B 10-K · filed 2024-02-20 |
| 2022-12-31 | $36.36B 10-K · filed 2023-02-17 |
| 2021-12-31 | $37.38B 10-K · filed 2022-02-18 |
| 2020-12-31 | $43.69B 10-K · filed 2021-02-19 |
| 2019-12-31 | $41.71B 10-K · filed 2020-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |